Health Technology · Pharmaceuticals: Major · NSE: GLENMARK · data 2026-10-09
Glenmark Pharmaceuticals Limited
Health check: Strong (8.1/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹2,293
Market cap
₹62,365 cr
P/E
36
P/B
—
ROE
14.1%
ROCE
29.2%
Debt / equity
0.06
Dividend yield
0.23%
1-year return
18.4%
52-week high
₹2,537.6
52-week low
₹1,792.6
Operating margin
20.2%
Growth
| Revenue (last 12 months) | ₹17,737 cr |
| Net profit (last 12 months) | ₹1,798 cr |
| Sales growth, 3 years (yearly) | 13.6% |
| Profit growth, 3 years (yearly) | 66.1% |
Similar companies
Alkem Laboratories Ltd. (ALKEM) · Biocon Limited (BIOCON) · Abbott India Limited (ABBOTINDIA) · Gland Pharma Ltd. (GLAND) · IPCA Laboratories Limited (IPCALAB)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open GLENMARK in NSE Scanner →